Management of glucocorticoid-induced osteoporosis

Nature Reviews Rheumatology

Volumn 6, Issue 2, 2010, Pages 82-88

  Compston, Juliet ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLONY STIMULATING FACTOR 1; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DEVELOPMENT; BONE TURNOVER; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FALL RISK ASSESSMENT; FRACTURE; HUMAN; LIFESTYLE MODIFICATION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 76649116231     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.259     Document Type: Review

References (73)

1. Compston, J. E. Emerging consensus on prevention and treatment of glucocorticoidinduced osteoporosis. Curr. Rheumatol. Rep. 9, 78-84 (2007).
2. Curtis, J. R. et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoidtreated patients. Arthritis Rheum. 52, 2485-2494 (2005).
3. Feldstein, A. C., Elmer, P. J., Nichols, G. A. & Herson, M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos. Int. 16, 2168-2174 (2005).
4. Duyvendak, M., Naunton, M., Atthobari, J., van den Berg, P. B. & Brouwers, J. R. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Osteoporos. Int. 18, 1429-1433 (2007).
5. Newman, E. D. et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos. Int. 17, 1428-1434 (2006).
6. Blalock, S. J., Norton, L. L., Patel, R. A. & Dooley, M. A. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 53, 732-739 (2005).
7. van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. QJM 93, 105-111 (2000).
8. van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 933-1000 (2000).
9. De vries, F. et al. Fracture risk with intermittent high-dose glucocorticoid therapy. Arthritis Rheum. 56, 208-214 (2007).
10. Van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39, 1383-1389 (2000).
11. van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777-787 (2002).
12. Ip, M., Lam, K., Yam, L., Kung, A. & Ng, M. Decreased bone mineral density in premenopausal asthma patients receiving longterm inhaled steroids. Chest 105, 1722-1727 (1994).
13. Toogood, J. H. et al. Bone mineral density and the risk of fracture in patients receiving longterm inhaled steroid therapy for asthma. J. Allergy Clin. Immunol. 96, 157-166 (1995).
14. wong, C. A. et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355, 1399-1403 (2000).
15. van Staa, T. P., Leufkens, H. G. & Cooper, C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16, 581-588 (2001).
16. van Staa, T. P., Bishop, N., Leufkens, H. G. & Cooper, C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos. Int. 15, 785-791 (2004).
17. Dalle Carbonare, L. et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16, 97-103 (2001).
18. Chappard, D. et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J. Bone Miner. Res. 11, 676-685 (1996).
19. Bressot, C. et al. Histomorphometric profile, pathophysiology and reversibility of corticosteroid induced osteoporosis. Metab. Bone Dis. Relat. Res. 1, 303-311 (1979).
20. Dempster, D. w. Bone histomorphometry in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 4, 137-147 (1989).
21. Dempster, D. w., Arlot, M. A. & Meunier, P. J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroidinduced osteoporosis. Calcif. Tissue Int. 35, 410-417 (1983).
22. Compston, J. et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos. Int. 19, 1247-1250 (2008).
23. Rubin, J. et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139, 1006-1012 (1998).
24. Hofbauer, L. C. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389 (1999).
25. Canalis, E. Mechanisms of glucocorticoid action in bone. Curr. Osteoporos. Rep. 3, 98-102 (2005).
26. Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H. & Takayanagi, R. Glucocorticoid suppresses the canonical wnt signal in cultured human osteoblasts. Biochem. Biophys. Res. Commun. 329, 177-181 (2005).
27. Smith, E. & Frenkel, B. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and -independent manner. J. Biol. Chem. 280, 2388-2394 (2005).
28. wu, Z., Bucher, N. L. & Farmer, S. R. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol. Cell Biol. 16, 4128-4136 (1996).
29. weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282 (1998).
30. weinstein, R. S. Glucocorticoids, osteocytes and skeletal fragility: the role of bone vascularity. Bone doi:10.1016/ j.bone.2009.06.030.
31. Lane, N. E. et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466-476 (2006).
32. Kanis, J. A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929-1936 (2002).
33. University of Sheffield. FRAX® -WHO Fracture Risk Assessment Tool [online] http:// www.shef.ac.uk/FRAX
34. Kanis, J. A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19, 893-899 (2004).
35. Luengo, M. et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroiddependent asthma. A one-year follow-up study. Am. Rev. Respir. Dis. 142, 104-107 (1990).
36. van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224-3229 (2003).
37. Homik, J. et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001347.doi:10.1002/14651858. CD001347.
38. Adachi, J. D. et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382-387 (1997).
39. Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299 (1998).
40. Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202-211 (2001).
41. De Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid- induced osteoporosis. N. Engl. J. Med. 355, 675-684 (2006).
42. Stoch, S. A. et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebocontrolled clinical trial. J. Rheumatol. 36, 1705-1714 (2009).
43. Cohen, S. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309-2318 (1999).
44. Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroidinduced osteoporosis in men and women: a randomized trial. European Corticosteroid- Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006-1013 (2000).
45. wallach, S. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277-285 (2000).
46. Reid, D. M., Adami, S., Devogelaer, J. P. & Chines, A. A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 69, 242-247 (2001).
47. Ringe, J. D., Dorst, A., Faber, H., Ibach, K. & Sorenson, F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14, 801-807 (2003).
48. Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253-1263 (2009).
49. weinstein, R. S. et al. Promotion of osteoclast survival and antagonism of bisphosphonateinduced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109, 1041-1048 (2002).
50. Khan, A. A. et al. Bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 36, 478-490 (2009).
51. Ing-Lorenzini, K. et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 32, 775-785 (2009).
52. Compston, J. E. Skeletal actions of intermittent parathyroid hormone: effects on bone remodeling and structure. Bone 40, 1447-1452 (2007).
53. Lane, N. E. et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627-1633 (1998).
54. Lane, N. E. et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoidinduced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. 15, 944-951 (2000).
55. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039 (2007).
56. Langdahl, B. L. et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos. Int. doi:10.1007/s00198-009-0917-y.
57. Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001).
58. Oxlund, H. et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39, 244-252 (2006).
59. Nishida, S. et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15, 717-723 (1994).
60. Jilka, R. L. et al. Increased bone formation by prevention of osteoblast apoptosis by parathyroid hormone. J. Clin. Invest. 104, 439-446 (1999).
61. Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346-3355 (2009).
62. Richy, F., Ethgen, O., Bruyere, O. & Reginster, J. Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos. Int. 15, 301-310 (2004).
63. Richy, F. et al. vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif. Tissue Int. 76, 176-186 (2005).
64. De Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid- induced osteoporosis. N. Engl. J. Med. 355, 675-684 (2006).
65. Devogelaer, J. P. et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. 17, 8-19 (2006).
66. Gourlay, M., Franceschini, N. & Sheyn, Y. Prevention and treatment strategies for glucocorticoid-induced osteoporosis. Clin. Rheumatol. 26, 144-153 (2007).
67. Guidelines working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. Glucocorticoidinduced osteoporosis: guidelines for prevention and treatment (Royal College of Physicians, London, 2002).
68. American College of Rheumatology ad hoc Committee on Glucocorticoid- induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis: 2001 update. Arthritis Rheum. 44, 1496-1503 (2001).
69. Brown, J. P. et al. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 (10 Suppl.), S1-S34 (2002).
70. Nawata, H. et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society of Bone and Mineral Research (2004). J. Bone Miner. Metab. 23, 105-109 (2005).
71. Geusens, P. et al. Review and evaluation of the Dutch guidelines for osteoporosis. J. Eval. Clin. Pract. 12, 539-548 (2006).
72. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online] www.nof.org (2008).
73. Compston, J. et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62, 105-108 (2009).